Xencor price to sales ratio XNCR

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 17.8×
7-year median: 10.3×
Against its 7-year history: 82nd; percentile: 0 is its lowest day, 100 its highest
7-year range: 3.5× to 35.2×
Peer median: 1.8×

Xencor's price to sales ratio is 17.8× as of Oct 23, 2026.

That is above its 7-year median of 10.3×, higher than on 82% of days in the last 7 years.

Over that time it ranged from 3.5× in Aug 2025 to 35.2× in Feb 2021.

The median for 10 large drugmakers of a similar size is 1.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.8×	5.4×	19.7×
2025	7.2×	3.5×	19.8×
2024	20.0×	6.7×	21.0×
2023	8.9×	5.4×	17.1×
2022	5.3×	3.7×	13.6×
2021	14.4×	10.2×	35.2×
2020	29.7×	9.6×	34.8×
2019	12.2×	11.3×	14.1×

Against its peers

Companies in Drug Manufacturers - General nearest Xencor's size, closest first, today.

Company	Price to sales ratio
XNCRXencor	17.8×
ANIPANI Pharmaceuticals	1.7×
HRMYHarmony Biosciences	2.2×
PAHCPhibro Animal Health	1.0×
PBHPrestige Consumer Healthcare	2.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
NRIXNurix Therapeutics	3.9×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.5×
OGNOrganon	0.6×
Peer median	1.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Xencor

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.